How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Healthcare and Pharmaceuticals · Forecast 2027–2033
Charcot-Marie-Tooth Disease Type I A Drug Market
- By Drug Class: Gene Therapy, Small Molecule Therapy, Antisense Oligonucleotides, Neurotrophic Factors, Immunomodulators
- By Mechanism of Action: Myelin Repair Agents, Axonal Regeneration Enhancers, Protein Expression Modulators, Inflammation Inhibitors, Mitochondrial Function Enhancers
- By Route of Administration: Oral, Intravenous, Intrathecal, Subcutaneous, Intramuscular
- By Patient Population: Pediatric Patients, Adult Patients, Elderly Patients, Genetically Confirmed CMT1A, Symptomatic vs Asymptomatic
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Gene Therapy leads By Drug Class at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 5 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
11 chapters · 258 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.63 →
- 10 Competitive Landscape 5 sections p.170 →
- 11 Company Profiles 5 players: SWOT & benchmarking p.178 →
Full report · locked preview
Everything inside the Charcot-Marie-Tooth Disease Type I A Drug Market report
A complete, evidence-based study - 11 chapters and 108 sections covering market size, segmentation across 4 axes, regional analysis and 5 company profiles, forecast to 2033.
Segmentation covered
Drug Class 5
Mechanism of Action 5
Route of Administration 5
Patient Population 5
Companies profiled
Addex Therapeutics Ltd
Affectis Pharmaceuticals AG
Genzyme Corp
Lead Discovery Center GmbH
Pharnext SA
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
5 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →Addex Therapeutics Ltd
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →Affectis Pharmaceuticals AG
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →Genzyme Corp
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.166 →Lead Discovery Center GmbH
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.173 →Pharnext SA
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.178 →Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Global · 2025–2033
$7,078M by 2033 · 5.8% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Gene Therapy47.8
- Small Molecule Therapy10.8
- Antisense Oligonucleotides12.7
- Neurotrophic Factors10.9
- Immunomodulators17.9
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$1,484M → $2,371M · 6.0%
Europe$1,034M → $1,737M · 6.7%
Asia Pacific$944.2M → $1,414M · 5.2%
Latin America$584.5M → $904.4M · 5.6%
Middle East and Africa$449.6M → $644.5M · 4.6%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →5.792026
5.802027
5.812028
5.832029
5.832030
5.842031
5.852032
5.882033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- Addex Therapeutics Ltd27.7
- Affectis Pharmaceuticals AG15.3
- Genzyme Corp14.4
- Lead Discovery Center GmbH9.0
- Pharnext SA5.6
- Others28.0
Segment contribution to growth (%)
Fig. 18 · p.39 →Drug Class12.5%
Mechanism of Action30.7%
Route of Administration22.6%
Patient Population34.1%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America33.5
- Europe24.6
- Asia Pacific20.0
- Latin America12.8
- Middle East and Africa9.1
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
5 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| Addex Therapeutics Ltd | 95 | 84 | 73 | 89 | 76 | 94 | 85 |
| Affectis Pharmaceuticals AG | 68 | 92 | 80 | 68 | 92 | 84 | 81 |
| Genzyme Corp | 77 | 67 | 82 | 69 | 76 | 73 | 74 |
| Lead Discovery Center GmbH | 67 | 67 | 76 | 70 | 77 | 75 | 72 |
| Pharnext SA | 56 | 75 | 72 | 54 | 51 | 61 | 62 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- Addex Therapeutics Ltd
- Affectis Pharmaceuticals AG
- Genzyme Corp
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| Addex Therapeutics Ltd | ✓ | ✓ | ◐ | ◐ | ✓ | ◐ |
| Affectis Pharmaceuticals AG | − | ✓ | ✓ | − | ✓ | ✓ |
| Genzyme Corp | ◐ | ✓ | ◐ | ◐ | ◐ | ✓ |
| Lead Discovery Center GmbH | ✓ | ◐ | ◐ | ✓ | ✓ | ◐ |
| Pharnext SA | ◐ | ◐ | ✓ | − | − | ◐ |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1Addex Therapeutics Ltd85
2Affectis Pharmaceuticals AG81
3Genzyme Corp74
4Lead Discovery Center GmbH72
5Pharnext SA62
Competitive tiers
§8.4 · p.172 →Leader2
Set the pace on share, breadth and innovation.
Addex Therapeutics LtdAffectis Pharmaceuticals AG
Challenger2
Strong scale, closing on the leaders.
Genzyme CorpLead Discovery Center GmbH
Contender1
Focused players with pockets of strength.
Pharnext SA
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Go-to-market strategy
Land Drug Class in North America, then scale across Charcot-Marie-Tooth Disease Type I A Drug Market — a $454M beachhead inside a $7.37B market.
Beachhead (SOM)$454Mobtainable near-term
Serviceable (SAM)$2.72Breachable market
Primary motionPartner-led + digitalgo-to-market
Time to scale3 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion92 fit
Gene Therapy
Best fit — highest urgency & budget in Drug Class.
Economic buyer79 fit
Small Molecule Therapy
Strong fit — clear ROI and a fast path to value.
End user69 fit
Antisense Oligonucleotides
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Drug Class in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Mechanism of Action & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + Route of Administration
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales41%
Partner / channel28%
Digital / self-serve22%
Marketplaces8%
Positioning & messaging
§GTM 2 · p.194 →For Drug Class leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Charcot-Marie-Tooth Disease Type I A Drug Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified39%
Sales qualified25%
Evaluation13%
Closed-won7%
$19.1KCAC
$95KLTV
5.0:1LTV : CAC
< 3 moCAC payback
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Investment thesis
Charcot-Marie-Tooth Disease Type I A Drug Market is a durable-growth opportunity — $3.56B by 2033, compounding at 9.0%.
TAM · 2025$1.79Btoday
TAM · 2033$3.56Bforecast
CAGR9.0%2027–2033
Cumulative$23.3Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$3.56BTotal addressable market
SAM$1.43BServiceable available market
SOM$277MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →9.0% CAGR
Demand compounds through 2033, outpacing GDP across Drug Class.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Drug Class moving from early to mainstream — durable secular demand.
Consolidation upside
5+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$3.56BLarge & growingTAM by 2033 at 9.0% CAGR
$1.43BServiceable nowreachable with today’s model
$277MBeachhead winobtainable near-term share
5+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$2.78BBear5.9% CAGR
$3.56BBase9.0% CAGR
$4.56BBull11.9% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Mechanism of Action optionality
- Customer concentrationBroaden installed base beyond top accounts
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Board pack · executive summary
Charcot-Marie-Tooth Disease Type I A Drug Market — a $1.81B market by 2033. Plan: grow share from 9.1% to 18.6%.
Market size · 2033$1.81Btotal addressable
Market CAGR7.7%2027–2033
Target share18.6%from 9.1% today
Revenue ambition$337Mby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 9.1% | 18.6% | Behind |
| Revenue | $166M | $337M | Ahead |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | On track |
| Segment coverage | 2 of 4 axes | 4 of 4 axes | On track |
| Gross margin | 30.4% | 38.0% | Behind |
| Customer retention | 89.0% | 93.8% | At risk |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Drug Class
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build Mechanism of Action capability
A defensible second engine — invest in Mechanism of Action to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Drug Class share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Mechanism of Action
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $50M capacity & capability investment
- Greenlight bolt-on M&A in Mechanism of Action
- Authorise North America expansion plan
- Fund R&D program for Drug Class leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownAhead
- Competitive share lossOn track
- Input-cost & supply riskBehind
- Regulatory / policy changeAt risk
- Execution & talentOn track
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Sales deck · value proposition
Win the Charcot-Marie-Tooth Disease Type I A Drug Market conversation — a $995M market you can size, segment and defend in minutes.
Market size · 2033$995Mtotal opportunity
Growth4.0%CAGR to 2033
Addressable buyers1,033+accounts in scope
Typical ROI5.1×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Drug Class
Goal Grow share in Drug Class
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →5.1×return on cost, year one
< 3 mopayback period
$84K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
5+players profiled in this market
Coverage includes
Addex Therapeutics LtdAffectis Pharmaceuticals AGGenzyme CorpLead Discovery Center GmbHPharnext SA
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Charcot-Marie-Tooth Disease Type I A Drug Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
Charcot-Marie-Tooth Disease Type I A Drug Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Healthcare and Pharmaceuticals · scroll →Dual Specificity Tyrosine Phosphorylation Regulated Kinase 1A Market
Market size, share, segmentation and regional forecast.
$3.3B market · 2025 base year
View reportCatenin Beta 1 Market
Market size, share, segmentation and regional forecast.
$5.8B market · 2025 base year
View reportDual Specificity Protein Kinase TTK Market
Market size, share, segmentation and regional forecast.
$504M market · 2025 base year
View reportDual Specificity Mitogen Activated Protein Kinase Kinase 1 Market
Market size, share, segmentation and regional forecast.
$1.0B market · 2025 base year
View reportCat Dewormers Market
Market size, share, segmentation and regional forecast.
$905M market · 2025 base year
View reportDomperidone Market
Market size, share, segmentation and regional forecast.
$1.2B market · 2025 base year
View reportDog Dewormers Market
Market size, share, segmentation and regional forecast.
$438M market · 2025 base year
View reportC1GLT Antibody Market
Market size, share, segmentation and regional forecast.
$1.3B market · 2025 base year
View reportBRAF Kinase Inhibitors Market
Market size, share, segmentation and regional forecast.
$3.9B market · 2025 base year
View reportBradykinin B1 Receptor Market
Market size, share, segmentation and regional forecast.
$1.0B market · 2025 base year
View reportDiagnostic Radioisotopes Market
Market size, share, segmentation and regional forecast.
$6.1B market · 2025 base year
View reportDiagnostic Nuclear Medicines Market
Market size, share, segmentation and regional forecast.
$1.0B market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report is readable online in full. Downloadable formats are available as optional $99 add-ons: a formatted PDF and a fully editable XLSX containing all underlying data tables - so you can re-chart, re-model, or drop any figure straight into your own deck.